Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...
Saved in:
| Published in | Antimicrobial Agents and Chemotherapy Vol. 35; no. 12; pp. 2580 - 2586 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Society for Microbiology
01.12.1991
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0066-4804 1098-6596 |
| DOI | 10.1128/AAC.35.12.2580 |
Cover
Loading…
| Abstract | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
|
|---|---|
| AbstractList | The safety and pharmacokinetics of recombinant CD4-immunoglobulin G (rCD4-IgG) were evaluated in a phase 1 study with dose escalation. A total of 16 patients, 6 with AIDS and 10 with AIDS-related complex, were evaluated at two university-affiliated hospital clinics. rCD4-IgG was administered once weekly for 12 weeks to four patients each at doses of 0.03, 0.1, 0.3, and 1.0 mg/kg of body weight. Dosing was intravenous for two patients in the 1.0-mg/kg dose group and intramuscular for the remaining patients. Dosing was intravenous for two patients in the 1.0-mg/kg dose group and intramuscular for the remaining patients. Pharmacokinetic, toxicity, and immunologic variables were monitored with all patients. Administration of rCD4-IgG was well tolerated, with no important clinical or immunologic toxicities noted. No subjects required dose reduction or discontinuation of therapy due to toxicity. No consistent changes were seen in human immunodeficiency virus antigen levels in serum or CD4 lymphocyte populations. The volume of distribution was small, and compared with that of rCD4, the half-life of the hybrid molecule was markedly prolonged following intramuscular or intravenous administration. The rate and extent of absorption following intramuscular dosing were variable. Intramuscular administration of rCD4-IgG appears to be inferior to intravenous dosing from a pharmacokinetic standpoint, with lower peak concentrations and variable absorption. After intravenous administration, peak concentrations of rCD4-IgG in serum (20 to 24 micrograms/ml) that have shown antiviral activity in vitro against more sensitive clinical isolates of human immunodeficiency virus were achieved. The peak concentrations in serum after intramuscular administration were below these levels. Treatment with rCD4-IgG was well tolerated at the doses administered to patients in this study but did not result in significant changes in CD4 lymphocyte counts or p24 antigen levels in serum. The safety and pharmacokinetics of recombinant CD4-immunoglobulin G (rCD4-IgG) were evaluated in a phase 1 study with dose escalation. A total of 16 patients, 6 with AIDS and 10 with AIDS-related complex, were evaluated at two university-affiliated hospital clinics. rCD4-IgG was administered once weekly for 12 weeks to four patients each at doses of 0.03, 0.1, 0.3, and 1.0 mg/kg of body weight. Dosing was intravenous for two patients in the 1.0-mg/kg dose group and intramuscular for the remaining patients. Pharmacokinetic, toxicity, and immunologic variables were monitored with all patients. After intravenous administration, peak concentrations of rCD4-IgG in serum (20 to 24 mu g/ml) that have shown antiviral activity in vitro against more sensitive clinical isolates of human immunodeficiency virus were achieved. The peak concentrations in serum after intramuscular administration were below these levels. Treatment with rCD4-IgG was well tolerated at the doses administered to patients in this study but did not result in significant changes in CD4 lymphocyte counts or p24 antigen levels in serum. Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology. For an alternate route to AAC .asm.org, visit: AAC The safety and pharmacokinetics of recombinant CD4-immunoglobulin G (rCD4-IgG) were evaluated in a phase 1 study with dose escalation. A total of 16 patients, 6 with AIDS and 10 with AIDS-related complex, were evaluated at two university-affiliated hospital clinics. rCD4-IgG was administered once weekly for 12 weeks to four patients each at doses of 0.03, 0.1, 0.3, and 1.0 mg/kg of body weight. Dosing was intravenous for two patients in the 1.0-mg/kg dose group and intramuscular for the remaining patients. Dosing was intravenous for two patients in the 1.0-mg/kg dose group and intramuscular for the remaining patients. Pharmacokinetic, toxicity, and immunologic variables were monitored with all patients. Administration of rCD4-IgG was well tolerated, with no important clinical or immunologic toxicities noted. No subjects required dose reduction or discontinuation of therapy due to toxicity. No consistent changes were seen in human immunodeficiency virus antigen levels in serum or CD4 lymphocyte populations. The volume of distribution was small, and compared with that of rCD4, the half-life of the hybrid molecule was markedly prolonged following intramuscular or intravenous administration. The rate and extent of absorption following intramuscular dosing were variable. Intramuscular administration of rCD4-IgG appears to be inferior to intravenous dosing from a pharmacokinetic standpoint, with lower peak concentrations and variable absorption. After intravenous administration, peak concentrations of rCD4-IgG in serum (20 to 24 micrograms/ml) that have shown antiviral activity in vitro against more sensitive clinical isolates of human immunodeficiency virus were achieved. The peak concentrations in serum after intramuscular administration were below these levels. Treatment with rCD4-IgG was well tolerated at the doses administered to patients in this study but did not result in significant changes in CD4 lymphocyte counts or p24 antigen levels in serum.The safety and pharmacokinetics of recombinant CD4-immunoglobulin G (rCD4-IgG) were evaluated in a phase 1 study with dose escalation. A total of 16 patients, 6 with AIDS and 10 with AIDS-related complex, were evaluated at two university-affiliated hospital clinics. rCD4-IgG was administered once weekly for 12 weeks to four patients each at doses of 0.03, 0.1, 0.3, and 1.0 mg/kg of body weight. Dosing was intravenous for two patients in the 1.0-mg/kg dose group and intramuscular for the remaining patients. Dosing was intravenous for two patients in the 1.0-mg/kg dose group and intramuscular for the remaining patients. Pharmacokinetic, toxicity, and immunologic variables were monitored with all patients. Administration of rCD4-IgG was well tolerated, with no important clinical or immunologic toxicities noted. No subjects required dose reduction or discontinuation of therapy due to toxicity. No consistent changes were seen in human immunodeficiency virus antigen levels in serum or CD4 lymphocyte populations. The volume of distribution was small, and compared with that of rCD4, the half-life of the hybrid molecule was markedly prolonged following intramuscular or intravenous administration. The rate and extent of absorption following intramuscular dosing were variable. Intramuscular administration of rCD4-IgG appears to be inferior to intravenous dosing from a pharmacokinetic standpoint, with lower peak concentrations and variable absorption. After intravenous administration, peak concentrations of rCD4-IgG in serum (20 to 24 micrograms/ml) that have shown antiviral activity in vitro against more sensitive clinical isolates of human immunodeficiency virus were achieved. The peak concentrations in serum after intramuscular administration were below these levels. Treatment with rCD4-IgG was well tolerated at the doses administered to patients in this study but did not result in significant changes in CD4 lymphocyte counts or p24 antigen levels in serum. |
| Author | J O Kahn P A Volberding C J Arri L D Kaplan A E Izu J Mordenti T L Hodges J E Groopman L M Bouvier A J Amman |
| AuthorAffiliation | New England Deaconess Hospital, Boston, Massachusetts 02215 |
| AuthorAffiliation_xml | – name: New England Deaconess Hospital, Boston, Massachusetts 02215 |
| Author_xml | – sequence: 1 givenname: T L surname: Hodges fullname: Hodges, T L organization: New England Deaconess Hospital, Boston, Massachusetts 02215 – sequence: 2 givenname: J O surname: Kahn fullname: Kahn, J O organization: New England Deaconess Hospital, Boston, Massachusetts 02215 – sequence: 3 givenname: L D surname: Kaplan fullname: Kaplan, L D organization: New England Deaconess Hospital, Boston, Massachusetts 02215 – sequence: 4 givenname: J E surname: Groopman fullname: Groopman, J E organization: New England Deaconess Hospital, Boston, Massachusetts 02215 – sequence: 5 givenname: P A surname: Volberding fullname: Volberding, P A organization: New England Deaconess Hospital, Boston, Massachusetts 02215 – sequence: 6 givenname: A J surname: Amman fullname: Amman, A J organization: New England Deaconess Hospital, Boston, Massachusetts 02215 – sequence: 7 givenname: C J surname: Arri fullname: Arri, C J organization: New England Deaconess Hospital, Boston, Massachusetts 02215 – sequence: 8 givenname: L M surname: Bouvier fullname: Bouvier, L M organization: New England Deaconess Hospital, Boston, Massachusetts 02215 – sequence: 9 givenname: J surname: Mordenti fullname: Mordenti, J organization: New England Deaconess Hospital, Boston, Massachusetts 02215 – sequence: 10 givenname: A E surname: Izu fullname: Izu, A E organization: New England Deaconess Hospital, Boston, Massachusetts 02215 |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5029794$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/1810192$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc1rFDEYxgep1G316k0IIl5k1iSTZJJDD8tWa6GgoJ7Du5nMTspMsiYz1v73ZrpLrULxEJLw_p736zkpjnzwtiheErwkhMr3q9V6WfEloUvKJX5SLAhWshRciaNigbEQJZOYPStOUrrG-c8VPi6OiSSYKLoo_JcOkkUEpXFqblFoUbQmDBvnwY-omwbwaH3OSjcMkw_bPmym3nl0gcbORtjdKXYwOuvHhG7c2KHV5flXBL65e5TR9jDaBuWcu97-el48baFP9sXhPi2-f_zwbf2pvPp8cbleXZXAcT2WQoEFkARoK3ndggJqTd0QWUnOhDCYKUUb2pCmASXYxlQSmo3Jh1vKJK1Oi7N93t20GWxjcnsRer2LboB4qwM4_XfEu05vw09NGWcVy_q3B30MPyabRj24ZGzfg7dhSrqmNRYYq_-CRGCFRT2D7_YgpIHq6zBFnxegCdazjTrbqCuuCdWzjZl-9bD_-8YPvuX4m0MckoG-jeCNS_cYx1TVah5jucdMDClF2_5J9Fhd9o_AuDHbG-Ytuf5x2eu9rHPb7sZFq_OUGsA8hH4D5jfSGg |
| CODEN | AACHAX |
| CitedBy_id | crossref_primary_10_1016_S0272_2712_18_30384_6 crossref_primary_10_1016_S0025_7125_05_70490_9 crossref_primary_10_1016_j_omtn_2018_09_018 crossref_primary_10_1002_1520_6017_200101_90_1_1__AID_JPS1_3_0_CO_2_K crossref_primary_10_1016_0167_7799_96_80921_8 crossref_primary_10_1016_0168_3659_94_90073_6 crossref_primary_10_1016_j_omtn_2018_09_003 crossref_primary_10_1089_aid_1994_10_1507 crossref_primary_10_1517_14712598_6_5_523 crossref_primary_10_1016_0005_2736_94_90219_4 crossref_primary_10_1073_pnas_2303509120 crossref_primary_10_3390_antib10030035 crossref_primary_10_1016_j_omtn_2017_04_017 crossref_primary_10_1089_scd_1_1995_4_463 crossref_primary_10_1002_rmv_440 crossref_primary_10_1093_bmb_58_1_43 crossref_primary_10_1097_00000441_199405000_00011 crossref_primary_10_1056_NEJM199306103282307 crossref_primary_10_3390_v2051069 crossref_primary_10_1016_S0889_8561_05_70012_6 crossref_primary_10_1111_j_1365_2710_1993_tb00875_x |
| ContentType | Journal Article |
| Copyright | 1992 INIST-CNRS |
| Copyright_xml | – notice: 1992 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 5PM |
| DOI | 10.1128/AAC.35.12.2580 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology Biology |
| EISSN | 1098-6596 |
| EndPage | 2586 |
| ExternalDocumentID | PMC245434 10.1128/AAC.35.12.2580 1810192 5029794 10_1128_AAC_35_12_2580 aac_35_12_2580 |
| Genre | Multicenter Study Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ IQODW CGR CUY CVF ECM EIF NPM RHF - 08R 0R 55 A AAPBV ABFLS ADACO ADBIT AFMIJ BXI GJ HZ ZA5 7T5 7U9 H94 7X8 5PM |
| ID | FETCH-LOGICAL-a507t-69aeaa81a2f857fa9a2ec7d18385466c04992d2d1dda964bc38adbcadb5e24823 |
| ISSN | 0066-4804 |
| IngestDate | Thu Aug 21 14:31:24 EDT 2025 Fri Sep 05 04:52:13 EDT 2025 Fri Sep 05 10:37:59 EDT 2025 Tue Dec 28 13:59:01 EST 2021 Sat Sep 28 08:42:51 EDT 2024 Wed Apr 02 07:08:26 EDT 2025 Thu Apr 24 23:00:00 EDT 2025 Tue Jul 01 03:25:35 EDT 2025 Wed May 18 15:37:23 EDT 2016 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Human Immunopathology IgG AIDS Glycoproteins Hemopathy Infection Viral disease T-Lymphocyte Phase I trial Antiviral AIDS related complex Pharmacokinetics |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a507t-69aeaa81a2f857fa9a2ec7d18385466c04992d2d1dda964bc38adbcadb5e24823 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/245434 |
| PMID | 1810192 |
| PQID | 16090679 |
| PQPubID | 23462 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_16090679 pubmed_primary_1810192 asm2_journals_10_1128_AAC_35_12_2580 proquest_miscellaneous_72706009 crossref_primary_10_1128_AAC_35_12_2580 crossref_citationtrail_10_1128_AAC_35_12_2580 pascalfrancis_primary_5029794 pubmedcentral_primary_oai_pubmedcentral_nih_gov_245434 highwire_asm_aac_35_12_2580 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 1900 |
| PublicationDate | 1991-12-01 |
| PublicationDateYYYYMMDD | 1991-12-01 |
| PublicationDate_xml | – month: 12 year: 1991 text: 1991-12-01 day: 01 |
| PublicationDecade | 1990 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States |
| PublicationTitle | Antimicrobial Agents and Chemotherapy |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 1991 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| SSID | ssj0006590 |
| Score | 1.5513422 |
| Snippet | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit... The safety and pharmacokinetics of recombinant CD4-immunoglobulin G (rCD4-IgG) were evaluated in a phase 1 study with dose escalation. A total of 16 patients,... |
| SourceID | pubmedcentral proquest asm2 pubmed pascalfrancis crossref highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2580 |
| SubjectTerms | Acquired Immunodeficiency Syndrome Acquired Immunodeficiency Syndrome - blood Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - immunology Adult AIDS-Related Complex AIDS-Related Complex - blood AIDS-Related Complex - drug therapy AIDS-Related Complex - immunology Antibiotics. Antiinfectious agents. Antiparasitic agents Antigens, Viral - drug effects Antigens, Viral - isolation & purification Antiviral agents Biological and medical sciences Biological Availability CD4 Immunoadhesins CD4 Immunoadhesins - blood CD4 Immunoadhesins - therapeutic use Dose-Response Relationship, Drug Humans Injections, Intramuscular Injections, Intravenous Kinetics Leukocyte Count Lymphocytes Male Medical sciences Middle Aged Pharmacology. Drug treatments Recombinant Proteins - therapeutic use Research Article |
| Title | Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex |
| URI | http://aac.asm.org/content/35/12/2580.abstract https://www.ncbi.nlm.nih.gov/pubmed/1810192 https://journals.asm.org/doi/10.1128/AAC.35.12.2580 https://www.proquest.com/docview/16090679 https://www.proquest.com/docview/72706009 https://pubmed.ncbi.nlm.nih.gov/PMC245434 |
| Volume | 35 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLXGEIgXBIWJMgZ-mMZDl9E4TuY8Vh10DA0qsUl7ixzHoZXWdKKtxPgJ_GrutZ0vaKXBQ6N82FbSe2L7OvecS8i-AgywIFdeLiLt8TTjnoh56imRawUdpvYVrnecf45OL_nZVXi1tfWrEbW0WqZH6udaXsn_WBXOgV2RJfsPlq0ahROwD_aFLVgYtney8XgCY1DPtxqxOO1D93aWmuAWl31veMK9KXJA5ij9YcLORz1LujI1nK6qI7kNPp58NZ8TcMczPBed2bBz_aM5jx0Uy-lsakScUGzgm2nCUOQmeuZIXdVi_ekclSQMMnrVWvMnObG0kN6X-tTNtaNC1IHII5jalwyJM8ebyBxtz29EfLieN4o8Lmyq4SNtO1vUMo1Cm9G27I2teEmJOtbsW0Ob88mN03AYrR8DGPIaBoPhURDiUm9dr6WrvanoPXKfgcvRN5187UrBfVo6k3sOJwAKLbxr14exXS5mrD3PKbWnMfRWLuDty23alHV-zZ_huY35zsUT8tg5KnRgUfeUbOmiQx7Y1KW3HfLw3AVldMjB2Mqf3x7Si5rNtzikB3RcC6PfPiOFwSv1qcErnee0gVdq8Er_xisdUYcnrFHilSJeKcKUAuxoE6_U4fU5ufzw_mJ46rl8H54Er2TpRbHUUgpfslyEx7mMJdPqOINBR4Q8ihR65yxjmZ9lMo54qgIhs1TBL9SMCxbskO1iXugXhPIgBYPlggmo6vdTqWBk47kWWcZ0nwddso9GStzLvEiML8xEArZMgjDxWYK27BKvNGKinGY-pm653lj-bVX-xqrFbCy5W2IigTtJpFStq3stmFSNhZhrLuZd8qaETQLDAX7jk4Wer-A5on6Ma8ObS4DD0gcvB0rsWJjVd4pifzHrkqiFv-o6KtG3rxTTiVGkZxwZ6i_v9qfukkd1D_GKbC-_r_QezOyX6Wvzyv0GS6jxow |
| linkProvider | ABC ChemistRy |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+1+study+of+recombinant+human+CD4-immunoglobulin+G+therapy+of+patients+with+AIDS+and+AIDS-related+complex&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Hodges%2C+T+L&rft.au=Kahn%2C+J+O&rft.au=Kaplan%2C+L+D&rft.au=Groopman%2C+J+E&rft.date=1991-12-01&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=35&rft.issue=12&rft.spage=2580&rft.epage=2586&rft_id=info:doi/10.1128%2FAAC.35.12.2580&rft.externalDocID=10.1128%2FAAC.35.12.2580 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |